Open AccessNKG2A, a New Kid on the Immune Checkpoint Block
Author(s) -
John B.A.G. Haanen,
Vincenzo Cerundolo
Publication year - 2018
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2018.11.048
Subject(s) - biology , immune checkpoint , immune system , cancer immunotherapy , antibody , cancer research , immunotherapy , cd8 , blocking antibody , cytotoxic t cell , immunology , genetics , in vitro
One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8 + T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom